|
|
Airsculpt Technologies Inc (NASDAQ: AIRS) |
|
|
|
| |
Airsculpt Technologies Inc 's Revenue per Employee
Quarterly Results, Trends, Rankings, Statistics, Cumulative Sales
Airsculpt Technologies Inc 's Revenue per employee fell on a trailing twelve month basis to $ 5,551,645, but the productivity of Airsculpt Technologies Inc 's employees remained above the company average. Within the Healthcare sector Employees of 12 other companies have achieved higher revenue per employee. While revenue per employee remained unchanged compared to the previous quarter at no. 171.Airsculpt Technologies Inc has 31 employees.
What is Sales per Employee Ratio?
|
Select the Comparisons :
|
|
Select the Ratio:
|
|
| AIRS Revenue per Employee |
(Mar 31 2025)
I. Quarter |
(Dec 31 2024)
IV. Quarter |
(Sep 30 2024)
III. Quarter |
(Jun 30 2024)
II. Quarter |
(Mar 31 2024)
I. Quarter |
| Y / Y Revenue Change |
-17.32 % |
-17.71 % |
-9.07 % |
-8.44 % |
3.94 % |
| Sales per Employee (TTM) $ |
5,551,645 |
5,817,742 |
6,089,677 |
6,226,613 |
6,378,194 |
| AIRS's Total
Ranking |
# 171 |
# 171 |
# 169 |
# 151 |
# 179 |
| Seq. Revenue Change |
0.49 % |
-7.92 % |
-16.58 % |
7.11 % |
0.03 % |
| Revenue per Employee Statistics |
| High |
Average |
Low |
| $ 6,378,194 |
$ 5,109,596 |
$ 1,117,774 |
| (Mar 31 2024) |
|
(Sep 30 2021) |
News about Airsculpt Technologies Inc |
|
By Miami Beach, Fla. ? AirSculpt Technologies, Inc. (NASDAQ: AIRS) is implementing strategic changes and updating projections for fiscal year 2024, yet the company s recent performance metrics signal a tougher road ahead. With the company gearing up to present at the ICR Conference 2025, questions linger about its capacity to regain traction in an increasingly competitive landscape.On January 13, 2025, AirSculpt issued a press release updating guidance for fiscal 2024. This announcement coincided with Yogi Jashnani?s recent appointment as CEO, effective January 7, 2025, succeeding Dennis Dean, who will transition back to his role as Chief Financial Officer. This significant leadership shift is positioned as a revitalization strategy, aimed at elevating the company s operational efficacy and market competitiveness.
|
|
In a significant move that underscores its commitment to innovation and excellence in the field of body contouring, AirSculpt Technologies, Inc. (NASDAQ:AIRS) has announced the appointment of Yogi Jashnani as the new Chief Executive Officer (CEO) and a member of the Board of Directors. This strategic leadership transition is set to take effect on January 7, 2025, with Yogi succeeding Dennis Dean, who has served as Interim CEO and will continue in his role as Chief Financial Officer.Miami Beach-based AirSculpt is recognized as a pioneering entity in the body contouring industry, specializing in premium procedures that cater to an increasingly discerning clientele. Under the leadership of Jashnani, the company is expected to harness his industry expertise and visionary outlook to drive further growth and enhance its competitive edge.
|
Date modified: 2025-05-04T13:54:56+00:00
| Companies with similar Revenue per Employee for 12 months ending Mar 31 2025, within Healthcare Sector | Revenue per Employee | Revenue 12 months ending Mar 31 2025 | Number of Employees Mar 31 2025 | | Axsome Therapeutics Inc | 9,361,708.33 | $ 449.362 Million | 48 | | Tarsus Pharmaceuticals Inc | 9,346,960.00 | $ 233.674 Million | 25 | | Ensign Group Inc | 8,572,391.47 | $ 4,423.354 Million | 516 | | Ardelyx inc | 6,955,884.62 | $ 361.706 Million | 52 | | Cryoport inc | 6,930,096.77 | $ 214.833 Million | 31 | | Geron Corp | 6,433,000.00 | $ 115.794 Million | 18 | | Progyny Inc | 6,156,101.52 | $ 1,212.752 Million | 197 | | Madrigal Pharmaceuticals Inc | 5,988,358.49 | $ 317.383 Million | 53 | | Gyre Therapeutics Inc | 5,591,277.78 | $ 100.643 Million | 18 | | Airsculpt Technologies Inc | 5,551,645.16 | $ 172.101 Million | 31 | | Agilon Health Inc | 5,361,645.48 | $ 5,988.958 Million | 1,117 | | Aurinia Pharmaceuticals Inc | 5,151,979.17 | $ 247.295 Million | 48 | | Catalyst Pharmaceuticals Inc | 5,043,830.19 | $ 534.646 Million | 106 | | Hims and Hers Health Inc | 4,481,731.16 | $ 1,783.729 Million | 398 | | Aytu Biopharma Inc | 4,280,187.50 | $ 68.483 Million | 16 | | Mirum Pharmaceuticals Inc | 4,213,900.00 | $ 379.251 Million | 90 | | Exelixis Inc | 4,061,699.65 | $ 2,298.922 Million | 566 | | Esperion Therapeutics Inc | 3,605,194.44 | $ 259.574 Million | 72 | | Arcellx Inc | 3,491,318.18 | $ 76.809 Million | 22 | | Xeris Biopharma Holdings Inc | 3,423,861.54 | $ 222.551 Million | 65 | | Novavax inc | 3,391,789.19 | $ 1,254.962 Million | 370 | | Day One Biopharmaceuticals Inc | 3,304,530.61 | $ 161.922 Million | 49 | | Xoma Royalty Corporation | 3,300,692.31 | $ 42.909 Million | 13 | | Adapthealth Corp | 3,195,236.22 | $ 3,246.360 Million | 1,016 | | Harmony Biosciences Holdings inc | 3,022,467.48 | $ 743.527 Million | 246 | | Tg Therapeutics Inc | 2,927,166.67 | $ 386.386 Million | 132 | | Evolus Inc | 2,925,346.15 | $ 380.295 Million | 130 | | Vaso Corporation | 2,822,290.32 | $ 87.491 Million | 31 |
|
